5.3. serum tumour markers. 5.3.1. pre-operative serum tumour markers serum afp, beta subunit human chorionic gonadotropin (β-hcg) ldh determined orchidectomy support diagnosis tc may indicative gct histology. 90% nsgct’s elevated afp β-hcg diagnosis 39% increased level . pure seminomas may also elevated β-hcg level diagnosis 30% cases . significant elevation afp patients seminomas raise concerns nsgct component. modest stable marker elevations may considered ‘normal’ clinical significance . thus, current tumour markers limitations due low sensitivity normal levels exclude presence disease. 5.3.2. serum tumour markers orchidectomy tumour markers need repeated following orchidectomy providing staging prognostic information . elevated pre-operatively normalisation may take several weeks serum half-lives afp β-hcg five seven days one three days respectively. remain elevated increase metastatic disease likely . marker normalisation orchiectomy however exclude possibility metastatic disease. addition staging marker levels used define risk stratification prognosis (table 4). also used monitor treatment response detect disease relapse . follow-up precise frequency testing well defined . 5.3.3. tumour markers micro rnas (mirnas) emerging potential new biomarkers. pre-operative elevation reported 80-90% sgct nsgct higher levels metastatic compared localised disease . number studies suggest higher discriminatory accuracy micro-rna (mirnas) (particularly mir-371a-3p) compared conventional gct markers diagnosis, clinical staging, treatment monitoring, predicting residual recurrent viable disease [63-65]. furthermore, may differentiate gct (stromal/non-germ cell originated) tumours . issues need resolved use routine clinical practice include laboratory standardisation, availability test and, importantly, prognostic validation . afp β-hcg mirna expressed teratoma limit use nsgct.